Alnylam Pharmaceuticals Q1 Earnings Call Highlights

1 hour ago 2

MarketBeat

Thu, April 30, 2026 astatine 11:04 AM CDT 7 min read

Alnylam Pharmaceuticals logo

Alnylam Stock Soars 65%: Find Out What’s Behind the Gains

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported what executives described arsenic a beardown commencement to 2026, driven by continued momentum successful its transthyretin (TTR) amyloidosis franchise and sustained show successful its uncommon illness portfolio. On the company’s first-quarter net call, CEO Yvonne Greenstreet said the 4th “demonstrated continued spot crossed the business,” highlighted by Alnylam’s archetypal 4th topping $1 cardinal successful combined nett merchandise revenues.

Product gross tops $1 cardinal arsenic TTR franchise drives maturation

Chief Commercial Officer Tolga Tanguler said Alnylam delivered $1.036 cardinal successful combined nett merchandise revenues successful Q1, up 121% year-over-year and up 4% sequentially from Q4 2025. The company’s TTR franchise remained the superior maturation engine, with $910 million successful planetary TTR nett revenues successful the quarter, up 6% from Q4 and 153% year-over-year, according to Tanguler.

→ Palantir Is Down 30%: Noise? Or a Signal to Accumulate?

3 biotech powerhouses poised to thrive amid assemblage rebound

In the U.S., Tanguler said TTR revenues accrued 9% versus Q4 and “more than 230% year-over-year,” reflecting continued maturation successful diligent demand. He besides noted that the $59 million U.S. gross summation implicit Q4 occurred contempt “fewer Q1 shipping weeks and lawsuit security reauthorization dynamics earlier successful the year,” which absorption had flagged previously.

Outside the U.S., Tanguler said planetary TTR revenues declined $7 cardinal from Q4, chiefly owed to “updated pricing successful Germany pursuing the ATTR-CM launch,” but grew 35% year-over-year. He added that planetary show exceeded expectations shared successful February, citing continued spot successful Japan and ongoing hereditary ATTR polyneuropathy (PN) show crossed planetary markets.

→ Did Qualcomm Just Put Apple successful Check?

Argenx's 28% Surge & Promising Product Propel Investor Confidence

Alnylam’s uncommon illness portfolio generated $126 million successful nett revenue, up 15% year-over-year. Tanguler said maturation was driven by accrued diligent demand, partially offset by “higher gross nett deductions crossed U.S. and planetary markets.”

U.S. motorboat dynamics: first-line adoption, prescriber growth, and adherence

Management emphasized doc adoption trends for AMVUTTRA successful ATTR cardiomyopathy (ATTR-CM). Tanguler said the motorboat has been supported by 3 factors: “physician penchant and utilization,” “access and affordability,” and “site of attraction infrastructure.” He besides pointed to expanding prescriber participation, noting that Alnylam has added “more than 1,200 unsocial caller U.S. prescribers since past March.”

Read Entire Article